A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC
Interventions: DRUG: PM8002|DRUG: nab-paclitaxel
Sponsor: Biotheus Inc.